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Summary Expression of the tumour suppressor gene p53 was examined in squamous cell carcinoma of the
head and neck using two p53 antibodies, PAb 421 and PAb 1801. Elevated p53 expression was found in 67%
of the 73 patients investigated. P53 expression was not found to correlate with whether the patient had been
previously treated or not, nor any of the clinico-pathological parameters. However a correlation was found
between the patients smoking history and positive p53 staining. Six out of seven non-smokers did not express
p53 whereas 29 of 37 heavy smokers were found to have elevated p53 expression (P <0.005). Also, of a group
of ten patients who had given up smoking more than 5 years ago, nine had elevated expression.
Epidemiological studies have shown a correlation between heavy smoking and head and neck cancer. The
present study indicates a genetic link for this correlation.
The proto-oncogene product p53 was initially identified as a
host cell protein bound to T antigen, the dominant trans-
forming oncogene of the SV40 virus (Lane & Crawford,
1979). It is a cellular protein expressed at low levels in
non-transformed cells; however, elevated levels are found in
certain tumours and in transformed cell lines (Dippold et al.,
1981; Crawford et al., 1981; Nigro et al., 1989; Iggo et al.,
1990). Normal levels of p53 act as tumour suppressor genes
in murine model systems (Finlay et al., 1989); but mutations
in the p53 have now been demonstrated in the murine gene
and can convert it into a dominant gene (Hinds et al., 1989).
Recently, p53 mutations have been demonstrated in several
human tumours (Crawford et al., 1981; Cattoretti et al.,
1988; Baker et al., 1989; Nigro et al., 1989; Takahashi et al.,
1989; Iggo et al., 1990; Chibia et al., 1990). It is of particular
interest that Iggo et al. (1990) demonstrated abnormal expres-
sion of p53 in lung tumours immunohistochemically and in
at least three cases, the abnormal staining pattern arose in
cells that had undergone p53 mutations. As the normal p53
protein has a very short half-life (6-20 min), it may be
inferred that the detection of the p53 protien is synonymous
with mutation because the mutant form has a half-life of up
to 6 h, probably due to stabilisation of the protein (Lane &
Benchimol, 1990). In addition Iggo et al. (1990) found in-
creased p53 oncoprotein staining in those lung cancers that
are associated with smoking. They reported elevated p53
protein levels in 14 of 17 (82%) squamous cell carcinomas
compared with 8 of 21 (38%) non squamous cell carcinomas.
Similarly, Chiba et al. (1990) reported that 65% of the lung
squamous cell carcinomas had p53 mutations compared with
36% of the non squamous tumours. The association of
smoking with squamous cell carcinoma of the lung provides
further evidence for a link between p53 mutations and smok-
ing.
Chiba et al. (1990) have undertaken the most comprehen-
sive analysis of p53 mutations in NSCLC (non small cell lung
cancer) tumours to date. They demonstrated mutations in 23
out of 51 primary NSCLC specimens; and that these muta-
tions are scattered throughout the open reading frame (ORF)
of the p53 gene. In addition, in several human tumours, there
appears to be a clustering of the p53 mutations in the large T
antigen binding regions (Nigro et al., 1989; Iggo et al., 1990;
Harlow et al., 1985; Bartek et al., 1990; Takahashi et al.,
1989 and Chiba et al. (1990). Chiba et al. (1990) have argued
that these regions may play an important part in controlling
the normal function of the p53 gene. A particularly interest-
ing observation was made by this group concerning the
nucleotide substitution pattern found in lung cancer. They
have examined all the published data available on p53 muta-
tions in human cancers and found that there was a G to T
transversion in 56% of p53 mutations in lung cancers, unlike
other tumours which have mainly G to A transversions. The
type of mutation is usually associated with a specific
mutagen, for example benzo(a)pyrene may case G to T trans-
versions in certain circumstances (Mazur et al., 1988),
whereas different mutagens cause the G to A transversions.
This evidence argues strongly in favour of lung cancer being
caused by a specific mutagen, adding weight to the associa-
tion between smoking and lung cancer.
We have previously demonstrated that there is elevated
expression of several oncogenes, (Ha-ras, Ki-ras, c-erbB-2
and c-myc) in the development of squamous cell carcinoma
of the head and neck (Field et al., 1986, 1987, 1989, 1990;
Field, 1991). We have reported a correlation between
elevated c-myc oncoprotein expression and poor prognosis
(Field et al., 1989), but as yet there is no published evidence
to demonstrate that amplification or point mutations of
oncogenes are associated with the clinical outcome of these
patients (Saranath, 1989; Rumsby et al., 1989; Sheng et al.,
1990; Field et al., unpublished).
Parada et al. (1984) have previously reported co-operation
between p53 tumour antigen and ras in cellular transforma-
tion. We have recently demonstrated that low levels of ras
p21 expression correlate with the disease free survival in
patients with SCC of the head and neck (Field et al., 1991).
Three per cent of the patients with ras negative staining were
alive 60 months after diagnosis whereas 54% of the patients
with positive staining were still alive after the same time
period (P <0.01).
In this study we have investigated the levels of p53 expres-
sion in 73 head and neck squamous cell carcinomas using
highly specific antibodies to p53, and we have correlated the
results with the already known clinical and pathological prog-
nostic factors, as well as the patients' smoking history.
Materials and methods
Seventy-three tumour specimens were collected from patients
with squamous cell carcinoma of the head and neck (treated
at the Royal Liverpool Hospital, Department of Otorhino-
laryngology by PMS), 38 patients were previously untreated
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whereas 35 had previous treatment. The tissue sections were
fixed in formalin and embedded in parffin wax. Serial sec-
tions of 5 Lm thickness were cut and processed for immuno-
cytochemistry. The following clinical and pathological data
were available: TNM staging using the UICC convention
(UICC 1987), site of tumour, details of previous treatment,
histopathological differentiation, the pathology of lymph
node metastases and follow up. The smoking pattern was
classified as non-smokers, moderate smokers (under 20
cigarettes per day) or heavy smokers (over 20 cigarettes per
day) or equivalent quantities of pipe tobacco. Patients who
had stopped smoking more than 5 years ago were considered
separately.
P53-PAb421 and the p53-PAb18O1 antibodies were used
for immunocytochemistry (Oncogene Science). P53-PAb421
reacts by immunoprecipitation with a 53 kD protein in a
broad range of mammalian species including humans.
PAb421 recognises a denaturation resistant epitope located
between amino acids 370-378 of p53 (Harlow et al., 1981;
Wade-Evans & Jenkins, 1985). The p53 protein was first
detected because of its ability to complex tightly with the
small DNA tumour virus SV40 large T antigen. (Harlow et
al., 1981). As the PAb421 antibody has been reported to
cross react with keratin (Harlow et al., 1985) we also used
the p53-PAbl801 antibody on 40 specimens. This antibody
reacts by immunoprecipitation with a 53 kD protein
specifically with the p53 human gene product. PAbl801
*recognises a denaturation resistant epitope between amino
acids 32 and 79 (Banks et al., 1986). In this study PAb421
and PAb1801 were detected by means of the avidin-biotin
peroxidase technique. Briefly, 5 gim sections were rehydrated
through graded alcohol to water and rinsed in 10mM Tris
buffered saline (TBS) at pH 7.6. Endogenous peroxidase
activity was eliminated by immersing the specimens for
20 min in acidified methanol containing 3% H202 and then
washed in water. The avidin - biotin - peroxidase complex
(ABC) method (Hsu et al., 1981) was used. The sections were
washed with PBS;. and incubated with the p53 antibodies
(diluted 1 in 200) for 1 h in PBS buffer with 1% bovine
serum albumin; goat anti-mouse (PAb421) or sheep anti-
mouse (PAbI8O1) avidin-biotin peroxidase vector (1 h); and
diaminobenzidine (DAB) sequentially. The staining pattern
was assessed by two pathologists and classified as; (+/-) for
negative or equivocal staining, (+) for moderate staining;
and (+ +) for intense staining. In controls p53 PAb421 and
PAb18O1 were omitted from the first stage and replaced with
the same concentration of a polyclonal mouse immuno-
globulin (Sigma, Poole) Also three cell lines were used as
controls for immunostaining; rat 208F cells were used as a
negative control; positive controls included the MCF-7
human breast cancer cell line and the MRSV3.1 human
breast epithelial cells immortalised with a retroviral vector
carrying the SV40 large T antigen gene (obtained from Dr
Joyce Taylor-Papadimitriou. ICRF). The tumour specimens
were also immunostained with the ras monoclonal antibody
Y13-259 (Furth et al., 1982).
Quantitative data were analysed by x2 or Fisher exact test
and weighted logistic regression (Armitage & Berry, 1987)
where appropriate.
Results
The 208F cell line showed negative staining with both the
p53 PAb420 and PAbl8O1 antibodies, whereas both the
MRSV3.1 cells immortalised with a retroviral vector carrying
the SV40 large T antigen and the MCF-7 cell line showed
nuclear staining (Figure la,b). Seventy-three head and neck
squamous cell carcinomas were investigated for elevated
levels of p53 gene expression, 67% of the squamous cell
carcinomas showed positive staining; 16% of these had
intense staining whereas 51% showed moderate staining.
Twenty specimens were investigated with both of these
antibodies and in all but two of the cases, similar staining
patterns were seen.
The normal p53 protein is restricted to the cell nucleus, but
we have found the p53 gene product in both the nucleus and
in the cytoplasm of the head and neck squamous cell car-
cinomas. No p53 oncoprotein staining was seen in the ad-
jacent normal tissues (Figure 2a,b,c,d).
Twenty-five of the 38 previously untreated patients and 24
of the 35 previously treated patients had positive p53 stain-
ing. As this difference was not significant it was felt appropri-
ate to group untreated and previously treated patients
together. No correlations were found between positive p53
staining and site, TNM staging, histological differentiation or
positive lymph nodes (data not included). Ras expression was
investigated in 56 of these specimens but was not found to
correlate with p53 expression in this study.
However when we analysed the patients smoking history
with the presence of p53 staining; six of seven non-smokers
were non-p53 expressers, whereas 29 of 37 heavy-smokers
had positive p53 expression (P <0.005) (Table I). However,
there were a group of patients that were either moderate or
Figure 1 a, Positive p53 oncoprotein staining in MCF-7 human breast cancer cell line (x 250) with PAbl8O1. b, Positive p53
oncoprotein staining in MRSV3.1 human breast epithelial cells immortalised with a retroviral vector carrying t the SV40 large T
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Figure 2 a, Negative p53 oncoprotein staining in squamous cell carcinoma cells (x 125) with PAb420. b, Moderate cytoplasmic
and nuclear staining (+) in squamous cell carcinoma cells (x 240) with PAb420. c, Intense (+ +) nuclear staining with PAbl80 in
squamous cell carcinoma cells which have not been counter stained (x 125). d, Intense cytoplasmic and nuclear staining (+ +) in
squamous cell carcinoma cells (x 125) with PAb420.
heavy smokers who did not have any p53 expression. Nine of
ten patients who had stopped smoking for 5 or more years
(range 5-18 years) had positive p53 staining in their tumour
specimens. In addition no significant difference in the staining
pattern was seen between the patients who had stopped
smoking and the patients with a history of heavy smoking
(P <0.05) (Figure 3). However there was a higher incidence
of p53 staining in the heavy smokers (29 of 37) compared
with the moderate smokers (ten out of 19)). No correlation
was found between smoking and any of the clinico-
pathological parameters.
Discussion
The results of this study indicates that elevated p53 expres-
sion correlates with a history of heavy smoking in patients
with head and neck squamous cell carcinoma.
The p53 protein has not been identified immunologically in
the nucleus of normal cells, as its level is so low (Iggo et al.,
1990), whereas in tumour tissue and cell lines, high levels of
the protein are found due to stabilisation of the protein
(Finlay et al., 1988). Cytoplasmic staining of the p53 gene
product has been previously reported in small cell carcinomas
of the lung using two monoclonal antibodies (PAb240 an
JG8). Similarly in this investigation p53 staining has been
found in the nucleus; a substantial amount was also observed
in the cytoplasm using two p53 antibodies, PAb420 and
PAbl80l.
Half of the patients presenting (to one of us, PMS) with
squamous cell carcinoma of the head and neck over the last
26 years were aged over 60 (n = 3392, median age 61 years)
and many of them have a long history of smoking. Thus
Table I p53 expression and smoking history in patients with
squamous cell carcinoma of the head and neck
p53 expression
Smoking history - + + +
Non-smokers 6 1 0
Stopped smoking 1 6 3
> 5 years
Moderate smokers 9 8 2
Heavy smokers 8 22 7
Total 24 37 12
Smoking history: Moderate: under 20 cigarettes per day. Heavy:
over 20 cigarettes per day. p53 staining: (-/+) negative or equivocal





Non Stopped Moderate Heavy
Smoker Smoking Smoking Smoking
Figure 3 Elevated p53 expression correlates with a history of
heavy smoking in patients with squamous cell carcinoma of the
head and neck. Smoking history: Moderate: under 20 cigarettes
per day; Heavy: over 20 cigarettes per day. p53 staining: (-/+)
negative or equivocal staining; (+) or (+ +) positive staining.
Statistical analysis: Non, stopped, moderate and heavy smokers.
P <0.002* (SD). Stopped smoking and heavy smokers. P = 0.371
(NSD). Non-smoker and heavy smoker. P = 0.03V (SD). *Chi-
squared. tFisher's Exact Test.
these results would suggest that carcinogens in smoke cause a
mutation in the p53 gene and may therefore be considered as
a probable initiation event in the development of the cancer.
In addition two of these patients gave up smoking over 18
years ago which would suggest that mutagen(s) in tobacco
cause a p53 mutation relatively early in the smoking history
of these patients and that further event(s) are required for the
development of the neoplasia.
There is overwhelming epidemiological evidence for a cor-
relation between heavy smoking and lung cancer (Doll &
Peto, 1976). Also the incidence of head and neck cancer, and
or oral cancer in particular appears to be directly related to
tobacco use. Furthermore, the relative risk increases with
duration and quantity smoked (Wynder & Stellman, 1977;
Silverman & Griffith 1972; Stell, 1972; Schmidt & Popham,
1981; Myers & Suen, 1989). This is the first report to date to
demonstrate a correlation between heavy smoking and aber-
rant expression of a specific gene.
Our results and those of Iggo et al. (1989) and Chiba et al.
(1990) indicate that there is a strong association between
both p53 mutations and over-expression in smoking related
cancers. We now plan to analyse p53 mutations in squamous
cell carcinoma of the head and neck and correlate the results
with our immunohistochemical data.
If these results are considered along the lines of the cur-
rently accepted model of p53 mode of action, it may be
suggested that the carcinogens in smoke damage the p53 gene
in such a way as to increase its expression, and it may be
argued that there has been both a loss of suppressor gene
function and a gain in the dominant transforming activity of
p53. Furthermore, tumours with no p53 staining may contain
either a normal p53 gene or have lost the expression of both
alleles or may contain a level of p53 mutant which cannot be
detected by p53 PAb421 of p53 PAbl801 antibodies on
formalin fixed sections.
In the long term, if it is demonstrated that smokers with
head and neck cancer have p53 mutations or p53 over-
expression, it may be possible to develop an anti-p53 specific
therapy for these patients.
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